A novel therapy with RNAi ARO-APOC3 as low as 25 mg significantly reduced mean maximal apolipoprotein C-III (APO-C3), triglycerides (TGs) and very low-density lipoprotein cholesterol (VLDL-C) with a favorable safety profile in healthy volunteers (HVs). These findings were presented Monday at the American Heart Association Scientific Session 2019 in Philadelphia by Christie Ballantyne, MD, of the Baylor College of Medicine, Houston.